FoleyRN, MurrayAM, LiS.Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol2005; 16(2): 489–495.
2.
KeithDS, NicholsGA, GullionCM, BrownJB, SmithDH.Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med2004; 164(6): 659–663.
3.
PatelUD, YoungEW, OjoAO, HaywardRA.CKD progression and mortality among older patients with diabetes. Am J Kidney Dis2005; 46(3): 406–414.
4.
FoleyRN, ParfreyPS, SarnakMJ.Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis1998; 32(5 Suppl 3): S112–S119.
5.
FoleyRN, WangC, CollinsAJ.Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc2005; 80(10): 1270–1277.
6.
MuntnerP, HeJ, AstorBC, FolsomAR, CoreshJ.Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol2005; 16(2): 529–538.
7.
KasiskeBL.Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis1998; 32(5 Suppl 3): S142–S156.
8.
LowrieEG, LewNL.Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis1990; 15(5): 458–482.
9.
TschopeW, KochM, ThomasB, RitzE.Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia. Nephron1993; 64(3): 354–358.
10.
NishizawaY, ShojiT, KakiyaR.Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl2003; (84): S117–S120.
11.
VaziriND.Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol2006; 290(2): F262–F272.
12.
RidkerPM, RifaiN, PfefferMA, SacksF, BraunwaldE.Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation1999; 100(3): 230–235.
13.
RosensonRS, TangneyCC.Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA1998; 279(20): 1643–1650.
14.
TreasureCB, KleinJL, WeintraubWS.Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med1995; 332(8): 481–487.
15.
MRC/BHFHeart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002; 360(9326): 7–22.
16.
TonelliM, IslesC, CurhanGC.Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation2004; 110(12): 1557–1563.
17.
ChoncholM, CookT, KjekshusJ, PedersenTR, LindenfeldJ.Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis2007; 49(3): 373–382.
18.
NavaneethanSD, PansiniF, PerkovicV.HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev2009; (2): CD007784.
19.
SandhuS, WiebeN, FriedLF, TonelliM.Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol2006; 17(7): 2006–2016.
20.
AsselbergsFW, DiercksGF, HillegeHL.Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation2004; 110(18): 2809–2816.
21.
DouglasK, O'MalleyPG, JacksonJL.Meta-analysis: the effect of statins on albuminuria. Ann Intern Med2006; 145(2): 117–124.
22.
WannerC, KraneV, MarzW.Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med2005; 353(3): 238–248.
23.
FellstromBC, JardineAG, SchmiederRE.Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med2009; 360(14): 1395–1407.
24.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med1998; 339(19): 1349–1357.
25.
DownsJR, ClearfieldM, WeisS.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998; 279(20): 1615–1622.
26.
SacksFM, PfefferMA, MoyeLA.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med1996; 335(14): 1001–1009.
27.
ShepherdJ, CobbeSM, FordI.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med1995; 333(20): 1301–1307.
28.
KobashigawaJA, KatznelsonS, LaksH.Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med1995; 333(10): 621–627.
29.
JohnsonBA, IaconoAT, ZeeviA, McCurryKR, DuncanSR.Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med2003; 167(9): 1271–1278.
30.
HoldaasH, FellstromB, JardineAG.Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet2003; 361(9374): 2024–2031.
31.
HoldaasH, JardineAG, WheelerDC.Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int2001; 60(5): 1990–1997.
32.
BaigentC, LandrayM, LeaperC.First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis2005; 45(3): 473–484.
